Hologic, Inc.: Breast Health Innovations, Market Penetration & Other Major Drivers

Hologic had a strong third quarter in fiscal 2024, demonstrating resilience and strategic efficiency in
navigating post-pandemic market conditions. The company reported total revenue of $1.01 billion
and a non-GAAP earnings per share of $1.06, both numbers topping their guidance predictions.
This marked a return to revenue growth, with a notable 3.1% increase compared to the previous
year, signaling a solid recovery trajectory after the challenges posed by COVID-19 and subsequent
global disruptions such as the chip shortage.